Dr. Tavallaei carried out his Ph.D. research in Biomedical Engineering at the Robarts Research Institute at Western University.
During his Ph.D. studies, he co-founded Vital Biomedical Technologies, a spinoff from Robarts that commercialized the world’s first fully MRI-compatible motion platform for quality assessment of MRI and MRI-guided therapy. After his Ph.D. studies, he completed the Medical Device Innovation Fellowship Program at Western University and the University of Minnesota. He did his postdoctoral fellowship at the Sunnybrook Research Institute (SRI), with the Department of Medical Biophysics at University of Toronto. Dr. Tavallaei is currently the Canada Research Chair (Tier II) in Systems and Devices for Cardiovascular Interventions at Toronto Metropolitan University, where he is an Assistant Professor of Biomedical Engineering. He is a Scientist at the Keenan Research Institute and is a visiting scientist at SRI. His research focuses on minimally invasive therapy and diagnosis of cardiovascular diseases. Dr. Tavallaei is also the co-founder and president of Magellan Biomedical, a spinoff company from SRI that aims to address significant clinical needs in cardiovascular interventions.